The Technical Analyst
Tenaya Therapeutics, Inc. [TNYA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Tenaya Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-2.33% $4.19
America/New_York / 19 apr 2024 @ 14:06
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 328.98 mill |
| EPS: | -1.680 |
| P/E: | -2.49 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 78.52 mill |
| Avg Daily Volume: | 0.614 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.49 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.42x |
| Company: PE -2.49 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.451 (-89.24%) $-3.74 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.72 - 4.69 ( +/- 11.52%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-05 | Hoey Timothy | Sell | 3 300 | Common Stock |
| 2024-02-23 | Hoey Timothy | Buy | 12 500 | Common Stock |
| 2024-02-23 | Hoey Timothy | Buy | 75 000 | Stock Option (Right to buy) |
| 2024-02-23 | Tingley Whittemore | Buy | 215 000 | Stock Option (Right to buy) |
| 2024-02-23 | Tingley Whittemore | Buy | 35 000 | Common Stock |
| INSIDER POWER |
|---|
| 99.37 |
| Last 96 transactions |
| Buy: 62 840 535 | Sell: 9 767 330 |
Forecast:
15:45 - $4.20
Live Trading Signals (every 1 min)
Forecast
1: 14:15 - $4.19
Forecast 2: 15:05 - $4.19
Forecast 3: 15:45 - $4.20
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.19 (-2.33% ) |
| Volume | 0.211 mill |
| Avg. Vol. | 0.614 mill |
| % of Avg. Vol | 34.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TNYA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $5.29 | N/A | Active |
|---|
TNYA
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-03-18 16:05:00 - Press Release
Tenaya Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Initial data from ongoing mypeak™-1 phase 1b of tn-201 for mybpc3-associated hcm expected in second half of 2024 on track to dose first patient in ridge™-1phase 1b clinical trial of tn-401 for pkp2-associated arvc in second half 2024 $47 million net proceeds from recent financing extends cash runway into second half of 2025 south san francisco, calif., march 18, 2024 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
2024-03-18 08:30:00 - Press Release
Tenaya Therapeutics Announces Publication Of Tn-401 Gene Therapy Preclinical Data In Nature Communications Medicine
Tn-401 aav9-based gene therapy being developed to treat the underlying cause of pkp2-associated arrhythmogenic right ventricular cardiomyopathy (arvc)
2024-02-27 16:30:00 - Press Release
Tenaya Therapeutics To Participate In Upcoming March Investor Conferences
South san francisco, calif., feb. 27, 2024 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in td cowen's 44th annual health care conference and leerink partners global biopharma conference 2024. details of participation are as follows:
2024-02-26 08:30:00 - Press Release
Tenaya Therapeutics Announces Publication Of Preclinical Hdac6 Inhibitor Data For Heart Failure With Preserved Ejection Fraction In Nature Communications
Highly selective small molecule hdac6 inhibitor effectively reversed heart failure and improved diastolic heart function alone or in combination with sglt2 inhibitor in murine models of disease
2024-02-08 08:00:00 - Press Release
Tenaya Therapeutics Announces Pricing Of Underwritten Offering
South san francisco, calif., feb. 08, 2024 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shares of its common stock at a purchase price of $4.499 per each pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant...
Latest News
2024-02-27 16:30:00 - GlobeNewsWire
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:
2024-02-26 10:56:14 - Zacks Investment Research
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
After reaching an important support level, Tenaya Therapeutics, Inc. (TNYA) could be a good stock pick from a technical perspective. TNYA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
2024-02-18 11:20:54 - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
2024-02-09 10:56:21 - Zacks Investment Research
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 273.1% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-01-26 13:01:03 - Zacks Investment Research
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-09-21 16:05:00 - GlobeNewsWire
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting
2023-08-31 16:05:00 - GlobeNewsWire
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 21st Annual Morgan Stanley Global Healthcare Conference taking place in New York City. Details of participation are as follows:
2023-05-15 11:26:13 - Zacks Investment Research
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 217.6% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-04-23 16:02:03 - InvestorPlace
3 Penny Stocks to Buy for 100% Returns
Penny stocks are one of the easiest ways to make multibagger gains in the market. However, when looking at penny stocks to buy, you have to be comfortable taking the risk that comes with these speculative names.
2023-04-20 14:46:29 - The Motley Fool
Why This Nasdaq Stock Caught Fire This Week
Two premium-laden buyouts sparked a wave of bargain hunting in biotech this week. Tenaya Therapeutics, a clinical-stage gene therapy company, was one of the industry's biggest winners.